Free Newsletter
Pharma racks up multibillion-dollar marketing bill
Drug marketing spending is staggering when you think about it: companies shell out $5 billion on DTC ads and $19 billion on so-called "doctor education." Their return on investment here isn't too shabby either: of the $279 billion spent on prescription drugs in 2006, Americans chose brand names 80 percent of the time.
The numbers tell a story that sharpens up what's becoming an old argument. Drug companies say it's all about educating patients and keeping doctors up-to-date on the latest science and technology. Critics say common conditions fixed with cheaper drugs go undertreated, but those that require expensive brand-name meds--the meds that are most heavily advertised to patients and docs alike--get plenty of attention. These branded drugs also contribute to skyrocketing healthcare costs: even a few billion off the top of that brand-name-fueled $279 billion could help. Agreed?
- read the spending report from The Los Angeles Times
Related Articles:
AMA to study the impact of drug advertising. Report
Does the FDA do enough to regulate drug ads? Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: